| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
31,939 |
25,726 |
$2.26M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
8,648 |
7,696 |
$2.05M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
7,737 |
6,837 |
$1.45M |
| A9150 |
Non-prescription drugs |
4,842 |
2,301 |
$1.44M |
| T1999 |
Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" |
28,871 |
14,873 |
$1.00M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
960 |
918 |
$782K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
4,513 |
4,261 |
$563K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,813 |
2,712 |
$520K |
| 0450 |
Emergency room services |
5,392 |
4,759 |
$454K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
2,087 |
2,014 |
$334K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,543 |
1,513 |
$322K |
| 80053 |
Comprehensive metabolic panel |
8,187 |
7,600 |
$300K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
4,095 |
3,781 |
$261K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
7,969 |
7,364 |
$250K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,602 |
1,493 |
$243K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
586 |
566 |
$213K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,467 |
1,411 |
$207K |
| 71045 |
Radiologic examination, chest; single view |
4,893 |
4,601 |
$204K |
| Z7502 |
|
5,311 |
5,141 |
$204K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,827 |
2,604 |
$191K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
4,166 |
3,914 |
$189K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
1,597 |
1,545 |
$179K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,068 |
1,034 |
$149K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,078 |
1,047 |
$103K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
9,510 |
8,468 |
$93K |
| 82962 |
|
2,453 |
1,854 |
$81K |
| 71046 |
Radiologic examination, chest; 2 views |
1,277 |
1,241 |
$72K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
5,576 |
4,892 |
$65K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,718 |
1,466 |
$61K |
| J3490 |
Unclassified drugs |
4,917 |
3,114 |
$57K |
| 84484 |
|
3,703 |
3,337 |
$56K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
500 |
190 |
$37K |
| 99070 |
|
2,009 |
1,129 |
$37K |
| 83880 |
|
921 |
860 |
$33K |
| 83605 |
|
2,056 |
1,903 |
$32K |
| 36415 |
Collection of venous blood by venipuncture |
359 |
301 |
$27K |
| 90715 |
|
617 |
609 |
$26K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,352 |
1,297 |
$26K |
| 16020 |
|
1,446 |
818 |
$26K |
| 83690 |
|
2,742 |
2,605 |
$24K |
| 87040 |
|
1,096 |
976 |
$23K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,550 |
2,365 |
$21K |
| 81001 |
|
3,311 |
3,153 |
$20K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
56 |
56 |
$19K |
| 0270 |
|
1,537 |
755 |
$19K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
328 |
325 |
$18K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,072 |
894 |
$17K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,986 |
1,875 |
$16K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
315 |
202 |
$15K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,201 |
1,128 |
$11K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
125 |
122 |
$11K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
77 |
76 |
$10K |
| 81025 |
|
1,176 |
1,146 |
$10K |
| J2060 |
Injection, lorazepam, 2 mg |
1,371 |
1,244 |
$10K |
| 81003 |
|
918 |
898 |
$9K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
417 |
260 |
$8K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
95 |
95 |
$8K |
| 83735 |
|
537 |
491 |
$6K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
747 |
641 |
$6K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
576 |
547 |
$6K |
| 73562 |
|
108 |
107 |
$5K |
| A9270 |
Non-covered item or service |
2,599 |
1,630 |
$5K |
| J1815 |
Injection, insulin, per 5 units |
15 |
13 |
$4K |
| 99231 |
Subsequent hospital care, per day, straightforward or low complexity |
136 |
77 |
$4K |
| 85610 |
|
750 |
694 |
$3K |
| Z7610 |
|
731 |
441 |
$3K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
72 |
27 |
$3K |
| 93971 |
|
12 |
12 |
$3K |
| 10060 |
|
97 |
95 |
$2K |
| 87186 |
|
179 |
169 |
$2K |
| 0949 |
|
67 |
37 |
$2K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
94 |
92 |
$2K |
| 96367 |
|
27 |
27 |
$2K |
| 73130 |
|
40 |
39 |
$2K |
| 99199 |
Unlisted special service, procedure or report |
41 |
24 |
$2K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
54 |
51 |
$2K |
| 80047 |
|
50 |
46 |
$2K |
| 87631 |
|
18 |
18 |
$2K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
94 |
92 |
$1K |
| 87077 |
|
27 |
25 |
$1K |
| 84443 |
Thyroid stimulating hormone (TSH) |
67 |
66 |
$1K |
| 82550 |
|
207 |
183 |
$847.23 |
| 73502 |
|
14 |
14 |
$786.67 |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
123 |
81 |
$780.75 |
| 84703 |
|
112 |
108 |
$756.32 |
| Z7500 |
|
20 |
14 |
$682.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
624 |
614 |
$651.72 |
| 71010 |
|
50 |
42 |
$552.36 |
| 71020 |
|
35 |
33 |
$547.27 |
| 85379 |
|
45 |
44 |
$525.38 |
| 73630 |
|
12 |
12 |
$502.31 |
| 80061 |
Lipid panel |
16 |
16 |
$370.56 |
| 73030 |
|
13 |
13 |
$365.47 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
56 |
53 |
$348.32 |
| 87081 |
|
38 |
38 |
$316.58 |
| 73610 |
|
13 |
13 |
$254.23 |
| J2358 |
Injection, olanzapine, long-acting, 1 mg |
31 |
25 |
$199.24 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
27 |
25 |
$186.42 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
13 |
13 |
$162.06 |
| 87430 |
|
13 |
12 |
$145.58 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
16 |
13 |
$58.18 |